PGIM Jennison Health Sciences Fund A (PHLAX)
34.85
-0.18
(-0.51%)
USD |
Jan 30 2026
Returns Chart
Key Stats
| Net Expense Ratio | Total Assets Under Management | Weighted Average Dividend Yield | Turnover Ratio (Generic) |
|---|---|---|---|
| 1.13% | 1.442B | 0.71% | 79.00% |
| 1 Year Fund Level Flows | 1 Year Total Returns (Daily) | Annualized Total Returns Since Inception (Daily) | Max Drawdown (Since Inception) |
| -367.06M | 11.16% |
Basic Info
| Investment Strategy | |
| The Fund seeks long-term capital appreciation. The Fund invests primarily in equity-related securities of U.S. firms engaged in the following industries: hospitals, nursing and residential care, health and medical insurance carriers, pharmaceutical and medicine companies, and medical equipment firms. |
| General | |
| Security Type | Mutual Fund |
| Equity Style | Multi Cap Growth |
| Broad Asset Class | Sector Equity |
| Broad Category | Equity |
| Global Peer Group | Equity Sector Healthcare |
| Peer Group | Health/Biotechnology Funds |
| Global Macro | Equity Industry Sector |
| US Macro | Sector Equity Funds |
| YCharts Categorization | -- |
| YCharts Benchmark | -- |
| Prospectus Objective | Health/Biotechnology Funds |
| Fund Owner Firm Name | PGIM Investments |
| Broad Asset Class Benchmark Index | |
| ^MSWNTR | 100.0% |
Net Fund Flows Versus Peer Group
1 Month
% Rank:
82
-192.68M
Peer Group Low
1.305B
Peer Group High
1 Year
% Rank:
85
-367.06M
-2.709B
Peer Group Low
1.036B
Peer Group High
3 Months
% Rank:
88
-557.78M
Peer Group Low
1.676B
Peer Group High
3 Years
% Rank:
82
-7.158B
Peer Group Low
593.46M
Peer Group High
6 Months
% Rank:
86
-1.267B
Peer Group Low
2.195B
Peer Group High
5 Years
% Rank:
82
-8.074B
Peer Group Low
3.237B
Peer Group High
YTD
% Rank:
82
-192.68M
Peer Group Low
1.305B
Peer Group High
10 Years
% Rank:
93
-13.11B
Peer Group Low
5.593B
Peer Group High
Date Unavailable
Risk
Performance Versus Peer Group
Annual Total Returns Versus Peers
As of February 01, 2026.
Asset Allocation
As of December 31, 2025.
| Type | % Net |
|---|---|
| Cash | -0.09% |
| Stock | 99.27% |
| Bond | 0.00% |
| Convertible | 0.00% |
| Preferred | 0.00% |
| Other | 0.82% |
Top 10 Holdings
| Name | % Weight | Price | % Change |
|---|---|---|---|
| Eli Lilly & Co. | 16.84% | 1037.15 | 1.27% |
| Thermo Fisher Scientific, Inc. | 5.54% | 578.61 | -2.29% |
| Danaher Corp. | 5.30% | 218.89 | -0.33% |
| Merck & Co., Inc. | 5.03% | 110.27 | 1.78% |
| Gilead Sciences, Inc. | 4.17% | 141.95 | 1.72% |
| argenx SE | 3.35% | 840.50 | -0.85% |
| CVS Health Corp. | 3.19% | 74.52 | 0.11% |
| Vertex Pharmaceuticals, Inc. | 3.19% | 469.90 | -1.22% |
| UnitedHealth Group, Inc. | 2.82% | 286.93 | -1.83% |
| UCB SA | 2.55% | 315.04 | 2.02% |
Fees & Availability
| Fees | |
| Actual 12B-1 Fee | 0.30% |
| Actual Management Fee | 0.73% |
| Administration Fee | -- |
| Maximum Front Load | 5.50% |
| Maximum Deferred Load | -- |
| Maximum Redemption Fee | -- |
| General Availability | |
| Available for Insurance Product | No |
| Available for RRSP | No |
| Purchase Details | |
| Open to New Investors |
|
| Minimum Initial Investment | 1000.00 None |
| Minimum Subsequent Investment | 100.00 None |
Basic Info
| Investment Strategy | |
| The Fund seeks long-term capital appreciation. The Fund invests primarily in equity-related securities of U.S. firms engaged in the following industries: hospitals, nursing and residential care, health and medical insurance carriers, pharmaceutical and medicine companies, and medical equipment firms. |
| General | |
| Security Type | Mutual Fund |
| Equity Style | Multi Cap Growth |
| Broad Asset Class | Sector Equity |
| Broad Category | Equity |
| Global Peer Group | Equity Sector Healthcare |
| Peer Group | Health/Biotechnology Funds |
| Global Macro | Equity Industry Sector |
| US Macro | Sector Equity Funds |
| YCharts Categorization | -- |
| YCharts Benchmark | -- |
| Prospectus Objective | Health/Biotechnology Funds |
| Fund Owner Firm Name | PGIM Investments |
| Broad Asset Class Benchmark Index | |
| ^MSWNTR | 100.0% |
Fundamentals
| General | |
| Distribution Yield | -- |
| Dividend Yield TTM (1-29-26) | 0.13% |
| 30-Day SEC Yield | -- |
| 7-Day SEC Yield | -- |
| Number of Holdings | 57 |
| Stock | |
| Weighted Average PE Ratio | 40.06 |
| Weighted Average Price to Sales Ratio | 13.28 |
| Weighted Average Price to Book Ratio | 10.33 |
| Weighted Median ROE | -37.23% |
| Weighted Median ROA | -3.07% |
| ROI (TTM) | -1.54% |
| Return on Investment (TTM) | -1.54% |
| Earning Yield | 0.0321 |
| LT Debt / Shareholders Equity | 1.407 |
| Number of Equity Holdings | 54 |
As of December 31, 2025
Growth Metrics
| EPS Growth (1Y) | 20.93% |
| EPS Growth (3Y) | 7.43% |
| EPS Growth (5Y) | 10.32% |
| Sales Growth (1Y) | 20.45% |
| Sales Growth (3Y) | 14.46% |
| Sales Growth (5Y) | 16.93% |
| Sales per Share Growth (1Y) | 34.48% |
| Sales per Share Growth (3Y) | 13.70% |
| Operating Cash Flow - Growth Rate (3Y) | 1.51% |
As of December 31, 2025
Fund Details
Top Portfolio Holders
| Name | % Weight |
|---|---|
| Portfolio A | 5.00% |
| Portfolio B | 3.50% |
| Portfolio C | 2.25% |
Excel Add-In Codes
| Name: =YCI("M:PHLAX", "name") |
| Broad Asset Class: =YCI("M:PHLAX", "broad_asset_class") |
| Broad Category: =YCI("M:PHLAX", "broad_category_group") |
| Prospectus Objective: =YCI("M:PHLAX", "prospectus_objective") |
| To find the codes for any of our securities and financial metrics, see our Complete Excel Reference. |